Paysign, Inc. filings document formal disclosures for a Nevada public company providing patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing. Recent Form 8-K reports furnish operating results and financial-condition updates tied to quarterly and annual earnings releases.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board and committee responsibilities, executive compensation, and beneficial ownership of Paysign securities. Other current reports include Regulation FD disclosures related to stockholder derivative action settlement materials, giving the filing record governance, litigation, ownership and reporting-context coverage in addition to financial results.
Paysign, Inc. CEO, director and 10% owner Mark Newcomer sold 50,000 shares of common stock on October 9, 2026, at a weighted average price of $15.3379 per share under a Rule 10b5-1 trading plan adopted September 12, 2025. After the sale, he directly held 9,113,002 shares. The shares were sold in multiple transactions at prices ranging from $15.3301 to $15.3410.
Paysign, Inc. (PAYS) director and EVP, Operations Joan M. Herman reported selling a total of 59,904 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. On September 15, 2026, 21,004 shares were sold at a weighted average price of $12.3819, and on September 16, 2026, 38,900 shares were sold at a weighted average price of $11.7437, across price ranges disclosed in the footnotes.
Paysign, Inc. (PAYS) reported that Chief Innovation Officer Michael C. Ngo, through Gamma Innovation LLC, sold a total of 150,000 shares of common stock in open-market transactions on September 8–9, 2026, at weighted average prices of $12.8494 and $12.74 per share, respectively. These are indirect sales by Gamma Innovation LLC, which Ngo solely owns, while he continues to hold 461,336 Paysign shares directly as of September 8, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
Paysign, Inc. (PAYS) reported that Chief Innovation Officer Michael C. Ngo had several equity-related transactions in the company’s common stock.
On March 19, 2025, 2,500,000 shares of restricted stock were issued indirectly via Gamma Innovation LLC as consideration under an Asset Purchase Agreement for substantially all of Gamma’s assets, vesting 1/5 on March 31, 2025 and annually thereafter. On the same date, Ngo received a direct grant of 500,000 restricted shares, vesting 1/5 on March 31, 2026 and annually thereafter, subject to continued service. On March 31, 2026, 38,664 shares were withheld by Paysign at $5.90 per share to satisfy tax withholding obligations on vested restricted stock.
Paysign, Inc. (PAYS) received a Rule 144 notice indicating an intended sale of its common stock. The notice covers up to 150,000 shares of Paysign common stock, with an aggregate market value of $1,950,000, to be sold through Merrill Lynch, Pierce, Fenner & Smith on Nasdaq. The shares are to be sold for the account of Michael C. Ngo, with a remark that the sale is on behalf of Gamma Innovations LLC. The securities relate to 1,000,000 shares of Paysign common stock originally received as consideration in the acquisition of Gamma Innovations, LLC.
Paysign, Inc. (PAYS) reported an initial statement of beneficial ownership on Form 3 for Michael C. Ngo, who serves as Chief Innovation Officer. The filing does not list any equity holdings or transactions for Ngo at this time and notes an exhibit for a Limited Power of Attorney.
Paysign, Inc. officer Turner Matthew Baker reported equity compensation and related tax transactions in Common Stock. On November 13, 2025, he received a grant of 233,333 shares of performance-based restricted stock, tied to an earnings target and vesting 1/3 on each of May 22, 2026, May 26, 2027, and May 24, 2028, subject to continued service. On February 3, 2026, he sold 15,057 shares at $4.16 per share, and on May 22, 2026, 50,681 shares at $6.72 per share were delivered or withheld, in both cases to satisfy tax withholding obligations on vesting restricted stock. No Rule 10b5-1 plan is reported.
Paysign, Inc. (PAYS) reported that Chief Technology Officer Bradley Kramer Cunningham disposed of common stock in several transactions. On May 29 and June 1, 2026, he sold a total of 13,000 shares of common stock at prices around $7.30–$7.80 per share, including sales executed in multiple trades at a weighted average price. On May 18, June 30, and July 31, 2026, a total of 46,378 shares of common stock were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock and performance-based restricted stock.
Paysign, Inc. (PAYS) reported the initial equity holdings of its Chief Technology Officer, Cunningham Bradley Kramer, via a Form 3 that principally describes prior restricted stock awards and their vesting schedules. The awards include time-based and performance-based restricted stock grants that vest in future years, contingent on continued service and, for one grant, achievement of an earnings target.
Paysign, Inc. (PAYS) reported initial insider holdings for officer Matthew Baker, President, Patient Affordability, in a Form 3. The filing lists a non-qualified stock option to purchase 15,000 shares of common stock at an exercise price of $3.87 per share, expiring on March 23, 2030, plus prior restricted stock awards with multi‑year vesting schedules. No new purchases or sales are reported, only existing equity awards and positions.